Literature DB >> 2494120

Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines.

V L Wong1, D J Rieman, L Aronson, B J Dalton, R Greig, M A Anzano.   

Abstract

Recombinant human interferon beta (rIFN-beta) inhibited in a time- and dose-dependent manner the proliferation of 18/18 human colon carcinoma cell lines in monolayer culture and 8/9 lines in a soft agar assay but had no effect on 4 human fibroblast cell lines. Maximal inhibition of cell proliferation by rIFN-beta required repetitive treatment (every 2 days) with lymphokine (50 units/ml). Furthermore, the inhibitory activity of rIFN-beta was neutralized by polyclonal antibodies against natural IFN-beta. In contrast to rIFN-beta, rIFN-alpha was inactive against all colon cell lines tested, and rIFN-gamma, with the exception of HT-29 cells, was similarly ineffective. These data demonstrate that rIFN-beta is a potent growth inhibitor of colon carcinoma cells in vitro, and suggest that studies on its mechanism of action may lead to a better understanding of the regulation of colon tumor cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2494120     DOI: 10.1002/ijc.2910430331

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

Review 1.  Genetic modification of stem cells for transplantation.

Authors:  M Ian Phillips; Yao Liang Tang
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

2.  Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer.

Authors:  Jennifer L Dembinski; Shanna M Wilson; Erika L Spaeth; Matus Studeny; Claudia Zompetta; Ismael Samudio; Katherine Roby; Michael Andreeff; Frank C Marini
Journal:  Cytotherapy       Date:  2013-01       Impact factor: 5.414

Review 3.  Mesenchymal stem cells engineered for cancer therapy.

Authors:  Khalid Shah
Journal:  Adv Drug Deliv Rev       Date:  2011-06-29       Impact factor: 15.470

4.  Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice.

Authors:  Takaya Matsuzuka; Raja Shekar Rachakatla; Chiyo Doi; Dharmendra Kumar Maurya; Naomi Ohta; Atsushi Kawabata; Marla M Pyle; Lara Pickel; Jennifer Reischman; Frank Marini; Deryl Troyer; Masaaki Tamura
Journal:  Lung Cancer       Date:  2010-10       Impact factor: 5.705

5.  Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model.

Authors:  C Ren; S Kumar; D Chanda; L Kallman; J Chen; J D Mountz; S Ponnazhagan
Journal:  Gene Ther       Date:  2008-07-03       Impact factor: 5.250

6.  A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma.

Authors:  J K Joffe; T J Perren; C Bradley; J Primrose; S Hallam; U Ward; J M Illingworth; P J Selby
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.

Authors:  A Villar-Grimalt; M T Candel; B Massuti; J Lizón; B Sánchez; A Frau; B Gorostidi; R Goedkoop
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

8.  Interferon-β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway.

Authors:  C Xie; D-Y Xie; B-L Lin; G-L Zhang; P-P Wang; L Peng; Z-L Gao
Journal:  Br J Cancer       Date:  2013-07-25       Impact factor: 7.640

9.  Human umbilical cord matrix-derived stem cells expressing interferon-β gene inhibit breast cancer cells via apoptosis.

Authors:  Ching-Ju Shen; Te-Fu Chan; Chien-Chung Chen; Yi-Chiang Hsu; Cheng-Yu Long; Chung-Sheng Lai
Journal:  Oncotarget       Date:  2016-06-07

10.  Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation.

Authors:  Elisabeth Müller; Martin Speth; Panagiotis F Christopoulos; Anna Lunde; Ajna Avdagic; Inger Øynebråten; Alexandre Corthay
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.